{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Stewart TG"],"funding":["NIDDK NIH HHS"],"pagination":["2354-2363"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC10656670"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["330(24)"],"pubmed_abstract":["<h4>Importance</h4>The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain.<h4>Objective</h4>To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19.<h4>Design, setting, and participants</h4>The ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less.<h4>Interventions</h4>Participants were randomized to receive fluvoxamine, 50 m"],"journal":["JAMA"],"pubmed_title":["Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial."],"pmcid":["PMC10656670"],"funding_grant_id":["K23 DK124654"],"pubmed_authors":["Mamon A","Jacklin K","Sexton C","Pillai R","Khetpal S","Brehaut S","Oragwu C","Castex J","Fortt T","Soileau BT","Sloan O","Jazayeri Y","Manis E","Mankowski K","Carrillo G","Morales Castillo L","Patel P","Cantu L","Reyes L","Fortt A","Dockery M","Woods A","Manning B","Luis Garcia J","Bianchi R","Dockery S","Singleton D","James V","De La Cruz M","Thicklin F","Yuan Y","Adhami E","Aamodt D","Karawan G","Ballmajo M","Vogel C","Abdelsayed D","Naquiallah D","Gutierrez A","Patel Y","Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV)-6 Study Group and Investigators","Patel V","Michelson E","Seithel M","McAdams MP","Koppinger N","Vecchiarelli A","Motel V","Fisher L","George-Adebayo C","Klicka K","Williams T","Quintero A","Dedier J","Campora P","Prabhu R","Harrington A","Quintero O","Kariyawasam D","Juma M","Roche A","Averett A","Summers J","Premas J","Lima S","Jones C","Pyram-Bernard N","Merkel A","Rivon M","Lindblom K","Lopez I","Harper A","Miller D","Baez J","Waite K","Miller C","Garcia Del Sol IT","Slandzicki A","Hurst T","Turner T","White B","Ramin S","Shahamatdar S","Pangburn H","Hicks M","Dixon S","Panaccione E","Grimes CZ","Sulkowski M","Vincent R","Gould C","Harrell F","Lambert AA","DeComarmond M","Heavlin H","Pullen M","Prieto S","Barbera A","Cohen J","Vaidya-Tank B","Mattox B","Rao S","Mehta M","Bowman J","Vance M","Griffin A","Wells K","Hallowell C","Shirey-Rice J","Archer A","Cardona OQ","Gupta A","Sekikawa A","Pardue V","Samraj J","Evans K","VandeWeerd C","Griffin M","Gupta M","Khizer S","Fraser R","Patterson TF","Okulicz J","Farlow B","Li J","Chen J","Linn D","Garcia M","Umana U","Umana V","Lozinski G","Gnoni M","Lamb D","Ginde AA","Ostrosky-Zeichner L","Perez Landabur RO","Heidish RS","Maria J","Adeyemi O","Cienki J","Lai J","Arnold J","Lim S","Torress D","Grady C","Adam SJ","Jordan J","Scott J","Parihar P","Raymond O","Vincent WK","Morris M","Urbat C","Rebolledo PA","Boulware DR","Marta M","Nielsen L","Prato N","Hassanien G","Pathak D","Vasquez M","Watts S","Daugherty H","Sommers S","Tan HN","Collins S","Lenert LA","Hernandez AF","Stelmash L","Martin D","Orozco D","Alicic R","Rowland T","Powers-Fletcher M","Sappington E","McTigue K","Jacques G","O'Donnell A","Cherukuri V","Stout E","Burns A","DeAlmeida S","Southwell A","Jackson PEH","Collins J","Bacallao N","Szwast E","Isache C","Shah N","Castro M","Wilson J","Moy J","Vergara L","Ofotokun I","Weeks K","Baxter J","Wiley H","Oguego N","Kerr B","Zhang C","Martin R","Achong A","Ramirez AM","Abdulghani A","Aziz M","Bozant E","Gentile N","Chan A","Swink W","Flys T","Wallan J","Del Pilar A","Munoz S","Ghaly E","Maldonado M","Callaghan-Brown A","Weir M","Duran B","Nwosu S","McCarthy MW","Ronan T","Wills W","Oyelakin M","Armas E","Spangler A","Szeto J","Jones-Ince I","Alleyne C","DeLong A","Burruss V","Samir Y","Vasbinder A","Brounce G","Dolor R","Seagle H","Love N","Tragus R","Manresa I","Herbert A","Mourad A","Felker GM","Jayaweera D","Pazier P","Marlin J","Parra D","D'Andrea M","Olofintuyi A","Curtis C","Spees R","Vasoya P","Adams M","Rivera E","Garcia Del Sol I","Wilder R","Roberts M","Nataraj J","Ellison L","Bhat N","Obregon S","Marcus J","Clement J","Gallegos C","Rohde M","Gabriel A","Adebayo A","Wang J","Vail J","Arena J","Amon A","Sevier M","Watson C","Goyal P","Paudel D","Cordero-Loperena D","Hanna GJ","Singh U","Liao V","Zapatero J","Bramante CT","Feliciano P","Meltzer A","Stewart TG","Naggie S","Adkins R","Richwine R","Gao Y","Mukunzi S","Williamson JC","Chopp J","Schwasinger-Schmidt T","Lightfeather A","Krishna A","Stone A","Rodriguez L","Klawson E","Dunsmore SE","Milstone A","Smith VE","Michal M","Ward M","Lindsell CJ","Gaytan-Alvarez D","Ast A","Cornejo A","Chi WN","Morton-Jost M","Ding X","Ruiz-Unger J","Gamboa Jackman J","Haughey HM","Rogers M","Nowell E","Chandrasekar N","Harrison J","Harding T","Abbott R","Rothman RL","Pagan I","Korzekwinski K","Robbs L","Ismail S","Talati R","Williamson J","Robinson M","Zamora Y","Bugajski A","Randle D","Mahadevan A","Grindstaff J","Roman A","Sheets M","Robinson P","McKee A","Crow M","Nguyen J","Pickell N","Smith J","Posey F","Almanzar M","Brown L","Graves J","Shenkman E","Beauchaine M","Vermillion K","Shah B","Olivo J","Cooper A","Kavtaradze D"],"additional_accession":[]},"is_claimable":false,"name":"Higher-Dose Fluvoxamine and Time to Sustained Recovery in Outpatients With COVID-19: The ACTIV-6 Randomized Clinical Trial.","description":"<h4>Importance</h4>The effect of higher-dose fluvoxamine in reducing symptom duration among outpatients with mild to moderate COVID-19 remains uncertain.<h4>Objective</h4>To assess the effectiveness of fluvoxamine, 100 mg twice daily, compared with placebo, for treating mild to moderate COVID-19.<h4>Design, setting, and participants</h4>The ACTIV-6 platform randomized clinical trial aims to evaluate repurposed medications for mild to moderate COVID-19. Between August 25, 2022, and January 20, 2023, a total of 1175 participants were enrolled at 103 US sites for evaluating fluvoxamine; participants were 30 years or older with confirmed SARS-CoV-2 infection and at least 2 acute COVID-19 symptoms for 7 days or less.<h4>Interventions</h4>Participants were randomized to receive fluvoxamine, 50 m","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Dec","modification":"2026-06-01T18:50:54.881Z","creation":"2026-05-19T03:07:10.385Z"},"accession":"S-EPMC10656670","cross_references":{"pubmed":["37976072"],"doi":["10.1001/jama.2023.23363"]}}